Clinical Data Psyched For Vilazodone NDA Filing In Second Half
This article was originally published in Pharmaceutical Approvals Monthly
Clinical Data has kicked off what could prove to be a pivotal year with a flurry of activity, including a new financing, the sale of its Cogenix pharmacogenomics services arm, and the publication of important clinical trial results. But investors are more concerned with what's coming in a couple of months: results from a second pivotal trial for its lead therapeutic candidate vilazodone and the subsequent NDA filing
You may also be interested in...
FDA requests additional Phase III comparative study and safety data for iloperidone.
A handful of companies are pursuing predictive genetic tests for evaluating psychiatric drugs. The need is apparent, and an early success could trigger a rapid shift in thinking about the sustainability of building a business around biomarkers in a therapeutic area sometimes considered the least likely to benefit near term from their development. That said, firms in this area--and elsewhere--must be wary of leaning too heavily on pharma companies as supportive partners.
Biopharma will outline its growth goals for 2022 over the coming weeks, with J&J, Novartis, AbbVie, Merck, Roche, Biogen and Lilly among the first to report.